NCT06207175 2024-01-23
A Study to Evaluate the Immunogenicity and Safety of Nonavalent Human Papillomavirus (HPV) Vaccine
Beijing Health Guard Biotechnology, Inc
Phase 3 Unknown
Clinical Trials
16 trialsNCT03900572 2023-04-13
A Study of Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine
Shanghai Zerun Biotechnology Co.,Ltd
Phase 1 Completed
NCT05694728 2023-01-23
A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV Vaccine
Beijing Health Guard Biotechnology, Inc
Phase 2 Completed
NCT05680454 2023-01-17
A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine
Beijing Health Guard Biotechnology, Inc
Phase 1 Completed
NCT05672966 2023-01-06
Phase I Clinical Trial of a Candidate HPV Vaccine
Wuhan BravoVax Co., Ltd.
Phase 1 Unknown
NCT05668572 2023-01-04
A Phase III Trial Evaluates the Efficacy, Immunogenicity and Safety Profile of HPV Vaccine
Beijing Health Guard Biotechnology, Inc
Phase 3 Unknown
NCT05662020 2022-12-27
A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China
Beijing Health Guard Biotechnology, Inc
Phase 3 Active not recruiting
NCT00231413 2019-12-12
Human Papilloma Virus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Bio's Novel HPV Vaccine.
GlaxoSmithKline
Phase 2 Completed
NCT00309166 2018-09-17
Evaluation of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV Vaccine in Young Males.
GlaxoSmithKline
Phase 2 Completed
NCT03085381 2018-09-14
A Phase I Study of Quadrivalent HPV Recombinant Vaccine
Shanghai Bovax Biotechnology Co., Ltd.
Phase 1 Completed
NCT00541970 2018-08-17
Partially Blind Study to Evaluate Immunogenicity & Safety of GSK Bio's HPV Vaccine 580299 in Healthy Women Aged 9-25 Yrs
GlaxoSmithKline
Phase 1 Completed
NCT00578227 2018-08-17
Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus Vaccine With Another Vaccine in Healthy Female Subjects
GlaxoSmithKline
Phase 3 Completed
NCT00652938 2018-08-17
Evaluation of Immunogenicity and Safety of Human Papillomavirus (HPV) Vaccine Co-administered With Another Vaccine in Healthy Female Subjects
GlaxoSmithKline
Phase 3 Completed
NCT01984697 2018-08-08
V503-010
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00552279 2018-06-25
Immunogenicity and Safety of GlaxoSmithKline Biologicals' Huma Papillomavirus (HPV) Vaccine 580299 in Healthy Females 15 - 25 Years of Age
GlaxoSmithKline
Phase 3 Completed
NCT00496626 2017-04-17
An Immunogenicity and Safety Study of Gardasil® in Chinese Subjects (V501-030)(COMPLETED)
Merck Sharp & Dohme LLC
Phase 3 Completed